Current Status of Cytotoxic Chemotherapy in Hormone Refractory Prostate Cancer

Heidenreich, Axel; Knobloch, Rolf von; Hofmann, Rainer

doi:10.1159/000052426

Cited by 40 publications

(17 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median survival of our study population (13+ months) was slightly better than that found in most series (8 -10 months) treated with other cytotoxic drugs or placebo (Tannock et al, 1996;Heidenreich et al, 2001;Kelly et al, 2001). Although ours was not a randomised trial, it is possible that an active and safe chemotherapy such as weekly epirubicin may prolong survival with a relatively good quality of life in HRPC patients.…”

Section: Discussioncontrasting

confidence: 53%

Weekly epirubicin in patients with hormone-resistant prostate cancer

et al. 2002

View full text Add to dashboard Cite

The aim of this study was to investigate the benefit of weekly epirubicin in the treatment of metastatic hormone-resistant prostate cancer. One hundred and forty-eight patients with metastatic hormone-resistant prostate cancer received weekly 30-min intravenous infusions of epirubicin 30 mg m 2 of body surface area. The primary end-point was palliative response, defined as a reduction in pain intensity and an improvement in performance status. The secondary end-points were the duration of the palliative response, quality of life and survival. Fifty-seven (44%) of the 131 evaluable patients met the primary criterion of palliative response after six treatment cycles and 73 (56%) after 12 cycles; the median duration of the response was 9 months (range 1 -11). The median global quality of life improved in 52% of the patients after six cycles and in 68% after 12 cycles. The 12-and 18-month survival rates were respectively 56 and 31%, with a median survival of 13+ months (range 1 -36). The treatment was well tolerated: grade 3 neutropenia was observed in 8% of the patients, grade 3 anaemia in 7%, and grade 3 thrombocytopenia in 3%. None of the patients developed grade 4 toxicity or congestive heart failure. Weekly epirubicin chemotherapy can lead to a rapid and lasting palliative result in patients with metastatic HRPC, and have a positive effect on the quality of life and survival.

show abstract

Section: Discussioncontrasting

confidence: 53%

Weekly epirubicin in patients with hormone-resistant prostate cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…ADT is also not curative and the cancer recurs as a metastatic and androgen-independent tumor in approximately 70-80% of the patients (9). Androgen-independent prostate cancer is thought to result from a number of factors such as genetic instability, inactivation of detoxifying enzymes, such as GST-γ, activation of certain oncogenes or amplification of the androgen receptor (AR) (10). Current treatment for such tumors includes docetaxel-based chemotherapy, which only offers a survival advantage of 3 months and is not curative (11,12).…”

Section: Introductionmentioning

confidence: 99%

Matrine inhibits proliferation and induces apoptosis of the androgen‑independent prostate cancer cell line PC-3

et al. 2011

View full text Add to dashboard Cite

Abstract. Current strategies to treat androgen-independent prostate cancer are associated with a number of challenges and are not yet curative. Matrine is a naturally occurring alkaloid extracted from the Chinese herb Sophora flavescens. Matrine has shown anti-proliferative properties in a number of types of cancer, including breast, gastric, lung and pancreatic tumors. Matrine was also found to promote apoptosis and inhibit invasion of cancer cells. We evaluated the antitumor effects of matrine on androgen-independent PC-3 prostate cancer cells. The effects of matrine on cell cycle progression and apoptosis of PC-3 cells were tested. Matrine-treated PC-3 cells underwent G0/G1 cell cycle arrest. There was a significant reduction in the number of S phase and G2/M phase cells in the treated group when compared to untreated cells. Flow cytometry, as well as Annexin-V/PI staining, showed a significant, dose-dependent increase in the number of early, as well as late, stage apoptotic cells in matrine-treated cells compared to untreated cells. There was also an increase in the number of necrotic cells in the matrine-treated group when compared to untreated cells. Matrine treatment resulted in increased levels of caspase-3 and Bax and decreased levels of Bcl-2. Our data suggest that matrine inhibits the proliferation of androgen-independent prostate cancer cells by causing G0/ G1 cell cycle arrest and promoting apoptosis. Matrine-induced apoptosis was mediated by downregulation of Bcl-2/Bax ratios and upregulation of caspase-3 levels. Based on our data, we suggest that matrine may be a novel addition to the current arsenal of strategies used to treat androgen-independent prostate cancer.

show abstract

“…Nevertheless, the clinical course of patients with hormone-resistant prostate cancer is dominated by bone metastases, which are difficult to evaluate and may be complicated by bone pain, pathological fractures and the deterioration of bone marrow reserves [23]. The use of palliative response may therefore substitute some measurement of tumour size that does not necessarily reflect patient benefit in hormone-resistant prostate cancer patients [24, 25]. Of the bone and tumoral markers, we found that the UCa/Cr ratio correlates better with a palliative response than PSA according to a recent study that identified UCa/Cr as the best marker for monitoring bone metastases from prostate cancer [7].…”

Section: Discussionmentioning

confidence: 99%

Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy

Petrioli¹,

Pozzessere²,

Messinese³

et al. 2003

Oncology

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate the activity and tolerability of docetaxel in patients with hormone-resistant prostate cancer previously exposed to chemotherapy. Methods: We enrolled 27 patients with hormone-resistant prostatic cancer that had progressed during first-line chemotherapy. The primary end-point was palliative response defined as a 2-point reduction in the 6-point present pain intensity scale, and an improvement in Karnofsky performance status of one 10-point category. The treatment consisted of weekly docetaxel 25 mg/m² body surface area administered by means of a 1-hour intravenous infusion with corticosteroid premedication. Results: The primary criterion of palliative response was met in 13 patients (48%) after eight treatment cycles; its median duration was 6 months (range 1–8). Mean global quality of life improved in 8 and 10 patients after respectively four and eight treatment cycles. After a median follow-up of 8 months, 21 patients had died: the median survival was 9+ months (range 2–18). Weekly docetaxel was very well tolerated: grade 3 neutropenia occurred in 1 patient and grade 3 anemia in 2. Conclusions: Weekly low-dose docetaxel is an effective and well-tolerated treatment for patients with hormone-resistant prostate cancer previously exposed to chemotherapy.

show abstract

Current Status of Cytotoxic Chemotherapy in Hormone Refractory Prostate Cancer

Cited by 40 publications

References 58 publications

Weekly epirubicin in patients with hormone-resistant prostate cancer

Weekly epirubicin in patients with hormone-resistant prostate cancer

Matrine inhibits proliferation and induces apoptosis of the androgen‑independent prostate cancer cell line PC-3

Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy

Contact Info

Product

Resources

About